Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Sawai Pharmaceutical Co. Ltd. is active in the Biotechnology and Pharmaceuticals technology area with a portfolio that currently shows 1 pending office action. This 1 pending office action is being handled by 1 distinct examiner. Additionally, the prosecution is occurring within 1 distinct art unit. The use of 1 distinct art unit suggests that the technical subject matter of the application falls under a specialized group at the patent office. Practitioners should note that having 1 distinct examiner means all current feedback originates from that individual.
The busiest examiner for this portfolio is KASSA, TIGABU, who is responsible for 1 busiest examiner pending office action. This 1 busiest examiner pending action is the same as the total 1 pending office action currently active for the company. Because the applicant is working with 1 distinct examiner, the prosecution process is tied to the patterns of that individual. The 1 pending office action in Biotechnology and Pharmaceuticals represents the current extent of the company's pending workload. This concentration in 1 distinct art unit and 1 distinct examiner allows for a prosecution strategy centered on the specific examiner and art unit identified in the data.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KASSA, TIGABU | 1 | 36.7% | +27.9% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17941129 | FILM-COATED GRANULE, PHARMACEUTICAL PREPARATION CONTAINING THE SAME, AND MANUFACTURING METHODS THEREOF | KASSA, TIGABU | 3d overdue |
| Art Unit | Apps |
|---|---|
| 1619 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17941129 | FILM-COATED GRANULE, PHARMACEUTICAL PREPARATION CONTAINING THE SAME, AND MANUFACTURING METHODS THEREOF | KASSA, TIGABU | 1619 | §103 | Final Rejection | 3d overdue | Pending | Sep 09, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSawai Pharmaceutical Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Tigabu Kassa has the most, with 1 of Sawai Pharmaceutical Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
